Anticavity drug enters Phase 2 Clinical Trial.
C3 Jian, Inc., a private company focused on providing improved oral health care, announced in March that the first Phase 2 Clinical Trial for its novel drug, C16G2, has begun under its U.S. Food and Drug Administration Investigational New Drug (IND) application. C16G2 is a synthetic peptide derived from a pheromone signaling platform technology called STAMPS (specifically targeted antimicrobial peptides). The drug targets the specific elimination of Streptococcus mutans. C3 Jian expects this Phase 2 study to be completed in late 2014.
The clinical protocol is a randomized, double-blind, placebo-controlled, four arm, safety and microbiology study in healthy adult subjects. The primary objective is to build on the safety profile of C16G2 administration in both dental gel and mouth rinse dosages. The study will also focus on targeting antimicrobial activity of these applications by measuring the reduction of Streptococcus mutans, as well as the total bacteria in dental plaque and saliva. With proper safety, the company expects to extend the Phase 2 program to assess C16G2 in children.
Source: C3 Jian, www.c3-jian.com
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||HEALTH; C16G2 of C3 Jian, Inc.|
|Article Type:||Brief article|
|Date:||May 1, 2015|
|Previous Article:||Remotely controlled magnetic nanoparticles stimulate stem cells to regenerate better, denser bone.|
|Next Article:||Sleeping with the television on: Part I.|